INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Inovio Pharmaceuticals
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Filamon LTD
Trogenix ltd
Eli Lilly and Company
Neonc Technologies, Inc.
Debiopharm International SA
M.D. Anderson Cancer Center
Lantern Pharma Inc.
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Essen Biotech
Essen Biotech
Grupo Español de Investigación en Neurooncología
Genenta Science
Sapience Therapeutics
Washington University School of Medicine
Cantex Pharmaceuticals
University of California, San Francisco
Institute of Cancer Research, United Kingdom
Tango Therapeutics, Inc.
Institute of Cancer Research, United Kingdom
InSightec
InSightec
Acerta Pharma BV
Case Comprehensive Cancer Center
AHS Cancer Control Alberta
Guangzhou Virotech Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
Mianyang Central Hospital
University of Miami
Universitair Ziekenhuis Brussel
Turning Point Therapeutics, Inc.
Tango Therapeutics, Inc.
GlaxoSmithKline
Incyte Corporation
NeuGATE Theranostics
University of Arizona
Jonsson Comprehensive Cancer Center
Duke University
Aveta Biomics, Inc.
M.D. Anderson Cancer Center
LigaChem Biosciences, Inc.
Shenzhen Geno-Immune Medical Institute
Hemerion Therapeutics
Rznomics, Inc.
Cedars-Sinai Medical Center
Kintara Therapeutics, Inc.